Cargando…

A nurse practitioner model of care in the era of direct acting antiviral therapy for hepatitis C virus infection

BACKGROUND AND AIM: Direct‐acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection has resulted in high rates of successful disease cure; however, not enough healthcare providers are available to deliver treatment to the population living with chronic HCV. To demonstrate that a nurse pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nario, Steffanie, Reynauld, Benhur, Blacklaws, Helen, Boden, Sharon, Sud, Rishi, Hawken, Glenn, Singh, Satbir, Herba, Karl, Panetta, James, Pang, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171160/
https://www.ncbi.nlm.nih.gov/pubmed/34124384
http://dx.doi.org/10.1002/jgh3.12552
_version_ 1783702379663720448
author Nario, Steffanie
Reynauld, Benhur
Blacklaws, Helen
Boden, Sharon
Sud, Rishi
Hawken, Glenn
Singh, Satbir
Herba, Karl
Panetta, James
Pang, James
author_facet Nario, Steffanie
Reynauld, Benhur
Blacklaws, Helen
Boden, Sharon
Sud, Rishi
Hawken, Glenn
Singh, Satbir
Herba, Karl
Panetta, James
Pang, James
author_sort Nario, Steffanie
collection PubMed
description BACKGROUND AND AIM: Direct‐acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection has resulted in high rates of successful disease cure; however, not enough healthcare providers are available to deliver treatment to the population living with chronic HCV. To demonstrate that a nurse practitioner (NP) model of care is non‐inferior to specialist gastroenterologist (SG) management of HCV infection, as measured by sustained viral response at 12 weeks (SVR(12)) after initiation of DAA therapy. DESIGN: Retrospective cohort database study. SETTING: Single‐center outpatient study, Central Coast Local Health District (CCLHD). PARTICIPANTS: All patients with chronic HCV treated in the CCLHD Liver Clinic in the period 3rd March 2016 to 31st May 2019 were retrospectively analyzed. In this time period, a total of 1638 patients with chronic HCV had completed treatment. Seven hundred and thirty‐four patients were excluded (733 pre‐PBS listing for DAAs and 1 not treated with DAA). Nine hundred and four patients were eligible for the study, of which 541 were managed by an SG, and 363 managed by an NP. MAIN OUTCOME MEASURES: Data were collected on patient demographics, genotype, fibrosis score, and presence of cirrhosis. Primary end point was number of patients achieving SVR(12). RESULTS: Of the 904 patients treated with DAA, 764 (84.5%) achieved SVR(12). There was no statistical difference (P > 0.05) in achieving SVR(12) between patients treated by an SP (n = 481, 88.9%) and those treated by an NP (n = 281, 77.4%). CONCLUSION: An NP model of care is non‐inferior to SG management of HCV infection, as evidenced by equivocal success in achieving SVR(12) between the two treatment groups. Therefore, an NP model of care is a viable option in the era of DAA therapy for HCV infection. Ongoing investment into the delivery of NP care could increase treatment uptake of HCV, with the aim of decreasing overall burden of disease.
format Online
Article
Text
id pubmed-8171160
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wiley Publishing Asia Pty Ltd
record_format MEDLINE/PubMed
spelling pubmed-81711602021-06-11 A nurse practitioner model of care in the era of direct acting antiviral therapy for hepatitis C virus infection Nario, Steffanie Reynauld, Benhur Blacklaws, Helen Boden, Sharon Sud, Rishi Hawken, Glenn Singh, Satbir Herba, Karl Panetta, James Pang, James JGH Open Original Articles BACKGROUND AND AIM: Direct‐acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection has resulted in high rates of successful disease cure; however, not enough healthcare providers are available to deliver treatment to the population living with chronic HCV. To demonstrate that a nurse practitioner (NP) model of care is non‐inferior to specialist gastroenterologist (SG) management of HCV infection, as measured by sustained viral response at 12 weeks (SVR(12)) after initiation of DAA therapy. DESIGN: Retrospective cohort database study. SETTING: Single‐center outpatient study, Central Coast Local Health District (CCLHD). PARTICIPANTS: All patients with chronic HCV treated in the CCLHD Liver Clinic in the period 3rd March 2016 to 31st May 2019 were retrospectively analyzed. In this time period, a total of 1638 patients with chronic HCV had completed treatment. Seven hundred and thirty‐four patients were excluded (733 pre‐PBS listing for DAAs and 1 not treated with DAA). Nine hundred and four patients were eligible for the study, of which 541 were managed by an SG, and 363 managed by an NP. MAIN OUTCOME MEASURES: Data were collected on patient demographics, genotype, fibrosis score, and presence of cirrhosis. Primary end point was number of patients achieving SVR(12). RESULTS: Of the 904 patients treated with DAA, 764 (84.5%) achieved SVR(12). There was no statistical difference (P > 0.05) in achieving SVR(12) between patients treated by an SP (n = 481, 88.9%) and those treated by an NP (n = 281, 77.4%). CONCLUSION: An NP model of care is non‐inferior to SG management of HCV infection, as evidenced by equivocal success in achieving SVR(12) between the two treatment groups. Therefore, an NP model of care is a viable option in the era of DAA therapy for HCV infection. Ongoing investment into the delivery of NP care could increase treatment uptake of HCV, with the aim of decreasing overall burden of disease. Wiley Publishing Asia Pty Ltd 2021-05-20 /pmc/articles/PMC8171160/ /pubmed/34124384 http://dx.doi.org/10.1002/jgh3.12552 Text en © 2021 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Nario, Steffanie
Reynauld, Benhur
Blacklaws, Helen
Boden, Sharon
Sud, Rishi
Hawken, Glenn
Singh, Satbir
Herba, Karl
Panetta, James
Pang, James
A nurse practitioner model of care in the era of direct acting antiviral therapy for hepatitis C virus infection
title A nurse practitioner model of care in the era of direct acting antiviral therapy for hepatitis C virus infection
title_full A nurse practitioner model of care in the era of direct acting antiviral therapy for hepatitis C virus infection
title_fullStr A nurse practitioner model of care in the era of direct acting antiviral therapy for hepatitis C virus infection
title_full_unstemmed A nurse practitioner model of care in the era of direct acting antiviral therapy for hepatitis C virus infection
title_short A nurse practitioner model of care in the era of direct acting antiviral therapy for hepatitis C virus infection
title_sort nurse practitioner model of care in the era of direct acting antiviral therapy for hepatitis c virus infection
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171160/
https://www.ncbi.nlm.nih.gov/pubmed/34124384
http://dx.doi.org/10.1002/jgh3.12552
work_keys_str_mv AT nariosteffanie anursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT reynauldbenhur anursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT blacklawshelen anursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT bodensharon anursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT sudrishi anursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT hawkenglenn anursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT singhsatbir anursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT herbakarl anursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT panettajames anursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT pangjames anursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT nariosteffanie nursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT reynauldbenhur nursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT blacklawshelen nursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT bodensharon nursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT sudrishi nursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT hawkenglenn nursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT singhsatbir nursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT herbakarl nursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT panettajames nursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection
AT pangjames nursepractitionermodelofcareintheeraofdirectactingantiviraltherapyforhepatitiscvirusinfection